ANHUI HUAHENG BIOTECHNOLOGY CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 121 CNY | -2.22% |
|
+2.16% | -3.91% |
| Apr. 22 | Anhui Huaheng Biotechnology's Q1 Profit Jumps 7% | MT |
| Apr. 22 | Anhui Huaheng Biotechnology's 2023 Profit Jumps 40% | MT |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 13,959 | 16,829 | 19,834 | 18,999 | - | - |
| Enterprise Value (EV) 1 | 13,959 | 16,829 | 20,728 | 19,663 | 19,312 | 18,687 |
| P/E ratio | 76 x | 52.6 x | 44 x | 30.1 x | 22.7 x | 18.4 x |
| Yield | - | 0.58% | 0.71% | 1.02% | 1.25% | 1.43% |
| Capitalization / Revenue | 14.6 x | 11.9 x | 10.2 x | 5.99 x | 4.63 x | 3.68 x |
| EV / Revenue | 14.6 x | 11.9 x | 10.7 x | 6.2 x | 4.71 x | 3.62 x |
| EV / EBITDA | 59.7 x | 41.9 x | 34 x | 21.8 x | 16.5 x | 12.8 x |
| EV / FCF | - | - | -21.6 x | -76.8 x | 47.9 x | 33.5 x |
| FCF Yield | - | - | -4.64% | -1.3% | 2.09% | 2.99% |
| Price to Book | 11.8 x | 11.4 x | 10.8 x | 8.18 x | 5.93 x | 4.96 x |
| Nbr of stocks (in thousands) | 156,600 | 157,180 | 157,540 | 157,044 | - | - |
| Reference price 2 | 89.14 | 107.1 | 125.9 | 121.0 | 121.0 | 121.0 |
| Announcement Date | 2/22/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 954.1 | 1,419 | 1,939 | 3,169 | 4,104 | 5,162 |
| EBITDA 1 | - | 233.8 | 401.2 | 609.7 | 903.6 | 1,169 | 1,465 |
| EBIT 1 | - | 186.3 | 342 | 513.3 | 735.4 | 963 | 1,208 |
| Operating Margin | - | 19.53% | 24.11% | 26.48% | 23.2% | 23.47% | 23.4% |
| Earnings before Tax (EBT) 1 | - | 190.8 | 343 | 508.7 | 735.9 | 962.7 | 1,208 |
| Net income 1 | 121.1 | 168.2 | 320 | 450.7 | 633.2 | 838.7 | 1,037 |
| Net margin | - | 17.63% | 22.56% | 23.25% | 19.98% | 20.44% | 20.08% |
| EPS 2 | 1.034 | 1.172 | 2.034 | 2.860 | 4.019 | 5.322 | 6.579 |
| Free Cash Flow 1 | - | - | - | -961.2 | -256 | 403 | 558 |
| FCF margin | - | - | - | -49.57% | -8.08% | 9.82% | 10.81% |
| FCF Conversion (EBITDA) | - | - | - | - | - | 34.48% | 38.08% |
| FCF Conversion (Net income) | - | - | - | - | - | 48.05% | 53.83% |
| Dividend per Share 2 | - | - | 0.6207 | 0.9000 | 1.240 | 1.514 | 1.728 |
| Announcement Date | 4/20/21 | 2/22/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 449.6 | 514.3 | 574.6 | 500.8 | 815.4 | 932.7 | 1,005 | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | - | 134.7 | 142.1 | 144.6 | 96.23 | 208.5 | 238.4 | 257 | - | - |
| Operating Margin | - | 29.95% | 27.63% | 25.16% | 19.22% | 25.57% | 25.57% | 25.57% | - | - |
| Earnings before Tax (EBT) 1 | - | 129.4 | 141.5 | 146.1 | 96.59 | 198 | 227.9 | 246.5 | - | - |
| Net income 1 | 81.2 | 110 | 128.7 | 130.8 | 86.57 | 138.8 | 164.8 | 181 | - | - |
| Net margin | - | 24.47% | 25.03% | 22.76% | 17.29% | 17.02% | 17.67% | 18% | - | - |
| EPS 2 | 0.5172 | 0.7020 | 0.8100 | 0.8300 | 0.5500 | 0.8809 | 1.046 | 1.149 | - | - |
| Dividend per Share 2 | - | - | - | - | - | 0.2873 | 0.2873 | 0.2873 | 0.3897 | 0.3897 |
| Announcement Date | 4/25/23 | 8/28/23 | 10/25/23 | 2/23/24 | 4/21/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | 894 | 664 | 312 | - |
| Net Cash position 1 | - | - | - | - | - | - | 312 |
| Leverage (Debt/EBITDA) | - | - | - | 1.466 x | 0.7348 x | 0.2673 x | - |
| Free Cash Flow 1 | - | - | - | -961 | -256 | 403 | 558 |
| ROE (net income / shareholders' equity) | - | 18.1% | 24.1% | 27.2% | 28% | 27.6% | 27.5% |
| ROA (Net income/ Total Assets) | - | 14.7% | 18.3% | - | 14% | 15% | 16.3% |
| Assets 1 | - | 1,144 | 1,751 | - | 4,539 | 5,594 | 6,363 |
| Book Value Per Share 2 | - | 7.560 | 9.420 | 11.60 | 14.80 | 20.40 | 24.40 |
| Cash Flow per Share 2 | - | 0.6100 | 2.270 | 1.910 | 3.250 | 6.860 | 6.310 |
| Capex 1 | - | 181 | 456 | 1,263 | 453 | 525 | 401 |
| Capex / Sales | - | 18.93% | 32.15% | 65.12% | 14.29% | 12.79% | 7.76% |
| Announcement Date | 4/20/21 | 2/22/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
121
CNY
Average target price
135.7
CNY
Spread / Average Target
+12.19%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -3.91% | 2.63B | |
| +2.37% | 29.86B | |
| +20.02% | 24.81B | |
| +6.21% | 11.19B | |
| +18.74% | 5.44B | |
| +20.42% | 4.54B | |
| -9.27% | 3.79B | |
| +4.52% | 3.12B | |
| +29.28% | 2.86B | |
| +4.70% | 2.41B |
- Stock Market
- Equities
- 688639 Stock
- Financials Anhui Huaheng Biotechnology Co., Ltd.
